A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2001
10/23/2001	CA2236368C Sublingual and buccal administration of selegiline
10/23/2001	CA2107150C Chromenic derivatives having a triene lateral chain, process for the preparation thereof and pharmaceutical compositions containing them
10/23/2001	CA2087606C (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
10/23/2001	CA2085570C Pyrrolidine derivatives, process for their preparation and pharmaceutical compositions containing them
10/23/2001	CA2080343C 5-benzyl barbiturate derivatives
10/23/2001	CA2047496C Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
10/23/2001	CA2040058C Alpha-mannosidase and fucosidase inhibitors
10/23/2001	CA2035749C Pyrroloazepine derivatives
10/23/2001	CA2023404C Phosphorylated glycosidase inhibitor prodrugs
10/18/2001	WO2001077687A2 Prion-binding peptidic ligands and methods of using same
10/18/2001	WO2001077357A2 Chromosomal vectors and uses thereof
10/18/2001	WO2001077339A1 Human pyruvate dehydrogenese phosphatase
10/18/2001	WO2001077338A2 Human protein kinases and protein kinase-like enzymes
10/18/2001	WO2001077327A1 THE HIGH BONE MASS GENE OF 11q13.3
10/18/2001	WO2001077297A1 Specific inhibitors of ribosome recycling factor (rrf)
10/18/2001	WO2001077174A2 Human transporters and ion channels
10/18/2001	WO2001077150A2 Serine-threonine kinase
10/18/2001	WO2001077146A2 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	WO2001077145A2 Integrin binding peptide derivatives
10/18/2001	WO2001077139A1 8ss-HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS
10/18/2001	WO2001077138A1 8β-SUBSTITUTED-11β-PENTYL- AND 11β-HEXYL-ESTRA-1,3,5(10)-TRIENE DERIVATIVES
10/18/2001	WO2001077137A1 Albumin fusion proteins
10/18/2001	WO2001077113A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
10/18/2001	WO2001077111A1 Pyrazolo-triazine derivatives as ligands for gaba receptors
10/18/2001	WO2001077109A2 Sodium salt of an azo derivative of 5-aminosalicylic acid
10/18/2001	WO2001077108A1 Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them
10/18/2001	WO2001077104A1 Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
10/18/2001	WO2001077101A1 Chemical compounds
10/18/2001	WO2001077100A2 Benzoamide piperidine compounds as substance p antagonists
10/18/2001	WO2001077097A2 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
10/18/2001	WO2001077094A1 Percyquinnin, a process for its production and its use as a pharmaceutical
10/18/2001	WO2001077093A1 Estrogen agonist/antagonist metabolites
10/18/2001	WO2001077086A1 SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION
10/18/2001	WO2001077085A1 Quinazoline compounds
10/18/2001	WO2001077079A2 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
10/18/2001	WO2001077073A1 Cathepsin cysteine protease inhibitors
10/18/2001	WO2001077069A1 Naphthamide neurokinin antagonists for use as medicaments
10/18/2001	WO2001077057A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	WO2001076654A1 Methods and compositions for treating intervertebral disc degeneration
10/18/2001	WO2001076644A2 Lipid-based systems for targeting diagnostic agents
10/18/2001	WO2001076638A2 Compositions for drug delivery
10/18/2001	WO2001076637A2 Peptide conjugates for drug delivery
10/18/2001	WO2001076629A1 Soluble beta amyloid precursor protein secretion promoters
10/18/2001	WO2001076627A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
10/18/2001	WO2001076616A1 Tamandarin and didemnin analogs and methods of making and using them
10/18/2001	WO2001076614A1 Remedies
10/18/2001	WO2001076602A1 Apomorphine derivatives and methods for their use
10/18/2001	WO2001076601A2 Pharmaceutical compositions comprising salmeterol and ipratropium
10/18/2001	WO2001076595A1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
10/18/2001	WO2001076589A1 Dermatological use and a dermatological preparation
10/18/2001	WO2001076586A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor
10/18/2001	WO2001076584A2 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	WO2001076580A1 Remedies
10/18/2001	WO2001076576A2 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
10/18/2001	WO2001076575A2 The treatment of respiratory diseases
10/18/2001	WO2001076573A2 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
10/18/2001	WO2001076572A2 Use of compatible solutes as substances having free radical scavenging properties
10/18/2001	WO2001076567A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	WO2001076564A1 Microprojectile delivery system and particulate product
10/18/2001	WO2001076556A2 Lipid-based drug delivery systems against parasitic infections
10/18/2001	WO2001076555A2 Lipid-based drug delivery systems for topical application
10/18/2001	WO2001076531A2 Bile acid containing prodrugs with enhanced bioavailability
10/18/2001	WO2001076530A2 Il-8 receptor antagonists
10/18/2001	WO2001076361A1 Animal and cell models for type ii diabetes and their use
10/18/2001	WO2001039724A3 Phosphonate compounds
10/18/2001	WO2001035933A3 A method of microencapsulation
10/18/2001	WO2001035901A3 Use of enzymes for skin expansion
10/18/2001	WO2001023540A3 P-glycoproteins and uses thereof
10/18/2001	WO2001023388A3 AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
10/18/2001	WO2001022090A9 Method for identifying compounds useful in the therapy of bone disorders
10/18/2001	WO2001020004A3 Protein phosphatase and kinase proteins
10/18/2001	WO2000078299A3 Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
10/18/2001	WO2000071518A3 Heterocyclic analgesic compounds and their use
10/18/2001	WO2000069898A8 Molecular interactions in allergy cells
10/18/2001	WO2000057837A9 Compositions and methods for effecting the levels of cholesterol
10/18/2001	WO2000039283A9 Use of cd40 engagement to alter t cell receptor usage
10/18/2001	WO2000035436A3 Treatment of arthritis with mek inhibitors
10/18/2001	WO2000020041A9 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent
10/18/2001	US20010031895 Intermediate p-cyclopropanoyl cumene compounds and derivatives, optionally having a 3-hydroxy group; 1-(benzoylalkyl)-4-(diphenylmethoxy)-piperidine compounds and 1-(a-hydroxybenzylalkyl)-4-(diphenylalkenyl)-piperidines
10/18/2001	US20010031874 Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
10/18/2001	US20010031873 Drug delivery, antitumor agents
10/18/2001	US20010031870 Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors
10/18/2001	US20010031788 Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects
10/18/2001	US20010031782 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
10/18/2001	US20010031777 Heterocyclic compounds and their therapeutic use
10/18/2001	US20010031772 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals
10/18/2001	US20010031770 Pyridoxal analogues and methods of treatment
10/18/2001	US20010031766 Prostaglandin receptor ligands
10/18/2001	US20010031757 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, N'-((1-(Aminoiminomethyl)4-piperidinyl) methyl)-N-(3,3- diphenylpropionyl)-L-proline amide
10/18/2001	US20010031733 Compound B as angiogenic agent in combination with human growth factors
10/18/2001	US20010031485 Nucleic acid coding for fusion protein which binds receptor; internalized by endocytosis; inhibits ribosomes and angiogenesis; therapy for tumors, metastasis, eye disorders, chronic inflammation and ischemic injuries
10/18/2001	US20010031261 Use of genetically engineered antibodies to treat multiple myeloma
10/18/2001	US20010031252 Endogenous immune response
10/18/2001	DE10019167A1 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma
10/18/2001	CA2414652A1 Animal and cell models for type ii diabetes and their use
10/18/2001	CA2406484A1 Method and composition for treating cancer by administration of apoptosis-inducing chemotherapeutic agents
10/18/2001	CA2406352A1 Peptide conjugates for drug delivery
10/18/2001	CA2406233A1 Compositions for drug delivery
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405793A1 Combination of organic compounds

1 ... 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 ... 1564